Advertisement
Screener

PMGC HOLDINGS INC. (ELAB) Operating Lease Cost

2.8 / 5 stars · 68/120 Roast Me

PMGC HOLDINGS INC. Operating Lease Cost

PMGC HOLDINGS INC. (ELAB) reported Operating Lease Cost of $119.22 thousand for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingLeaseCost · last filed 2024-11-14

  • PMGC HOLDINGS INC. operating lease, cost for the quarter ending 2024-09-30 was $39.74K, a 0.00% change year-over-year.
  • PMGC HOLDINGS INC. operating lease, cost for the quarter ending 2024-06-30 was $39.74K, a 25.64% increase year-over-year.
  • PMGC HOLDINGS INC. operating lease, cost for the quarter ending 2024-03-31 was $39.74K, a 25.64% increase year-over-year.
  • PMGC HOLDINGS INC. operating lease, cost for the quarter ending 2023-12-31 was $39.74K.
  • PMGC HOLDINGS INC. operating lease, cost for fiscal 2023 was $142.74K, a 93.41% increase from fiscal 2022.
  • PMGC HOLDINGS INC. operating lease, cost for fiscal 2022 was $73.80K.
Period endOperating Lease, Cost 3 monthOperating Lease, Cost 6 monthOperating Lease, Cost 9 monthOperating Lease, Cost 9 month as first filedOperating Lease, Cost 12 month
2024-09-30$39.74K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$79.48K
derived: sum of 2 quarters · filed 2024-11-14
$119.22K
10-Q · filed 2024-11-14
$158.96K
derived: sum of 4 quarters · filed 2024-11-14
2024-06-30$39.74K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$79.48K
10-Q · filed 2024-08-14
$119.22K
derived: sum of 3 quarters · filed 2024-08-14
$158.96K
derived: sum of 4 quarters · filed 2024-11-14
2024-03-31$39.74K
10-Q · filed 2024-05-15
$79.48K
derived: sum of 2 quarters · filed 2024-05-15
$119.22K
derived: sum of 3 quarters · filed 2024-11-14
$150.85K
derived: sum of 4 quarters · filed 2024-11-14
2023-12-31$39.74K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$79.48K
derived: sum of 2 quarters · filed 2024-11-14
$111.11K
derived: sum of 3 quarters · filed 2024-11-14
$142.74K
10-K · filed 2024-03-29
2023-09-30$39.74K
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14
$71.37K
derived: sum of 2 quarters · filed 2024-11-14
$103.00K
10-Q · filed 2024-11-14
$103.00M
10-Q · filed 2023-12-11
-$42.00M
derived: sum of 4 quarters · filed 2024-11-14
2023-06-30$31.63K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14
$63.26K
10-Q · filed 2024-08-14
-$42.04M
derived: sum of 3 quarters · filed 2024-08-14
2023-03-31$31.63K
10-Q · filed 2024-05-15
-$42.07M
derived: sum of 2 quarters · filed 2024-05-15
2022-12-31-$42.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29
$73.80K
10-K · filed 2024-03-29
2022-09-30$42.17M
10-Q · filed 2023-12-11

Similar stocks

Stock NameCountryMarket CapPE Ratio
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
Celularity Inc (CELU)United States$0.038B-0.34
BriaCell Therapeutics Corp. (BCTX)$0.037B
CervoMed Inc. (CRVO)United States$0.038B-1.39
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
Edesa Biotech, Inc. (EDSA)Canada$0.039B
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B